Replies to post #164 on Equity Field Notes from temporal sources

[DanWebzster]

APTO has two early-stage oncology with excellent commercial potential waiting to ENTER the clinic.

CEO may be the most hands-on chief in small cap biotech.

APTO-253 is an AML treatment that is on FDA clinical hold for manufacturing issues. Peak sales could be in the range of ~$550mn

CG806 is a pre-clinical drug with a potential in B-cell. It could address a $1B opty

Cash runway is into Q2/2019.

In 2017, it took an average:
$5mn to run a PH1 oncology study
$11mn to run a PH2 oncology study
$22mn to run a PH3 oncology study

APTO needs to raise ~$200mn to get across the finish line.